Skip to main content

Table 3 Estimated compound SUS and out-of-pocket spending with anti-diabetic therapies (updated in September 6th 2023)

From: Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model

 

Mean monthly costs (Brazilian real – R$)

Mean annual costs (R$ or Int$)

Drug class / Drug

Price 1

Price 2

Price 3

Price 4

Mean cost

sd

Market share-adjusted drug cost

Market share-adjusted drug class cost

Mean annual add-on drug class cost (R$)

Mean annual add-on drug class cost (Int$)

Biguanide

       

R$ 4,98

  

 Metformin 850 mg

R$ 2.10

R$ 2.01

R$ 3.49

R$ 2.67

R$ 2.57

R$ 0.68

R$ 4.98

   

Sulfonylureas

       

R$ 7.66

  

 Glybenclamide 5 mg

R$ 0.99

R$ 1.05

R$ 0.63

R$ 0.63

R$ 0.82

R$ 0.23

R$ 0.36

   

 Glimepiride

R$ 78.39

   

R$ 78.39

 

R$ 3.14

   

 Gliclazide 30 mg

R$ 10.48

R$ 13.92

R$ 10.28

 

R$ 11.56

R$ 2.05

R$ 4.16

   

Glitazone

       

R$ 2.68

511.92

202.34

 Pioglitazone 30-45 mg

R$ 47.00

R$ 42.00

R$ 39.00

 

R$ 42.66

R$ 4.04

R$ 2.68

   

GLP1 receptor agonists

       

R$ 28.50

8.505.54

3.361.87

 Liraglutide

R$ 686.00

R$ 482.02

R$ 496.75

 

R$ 554.92

R$ 113.75

R$ 23.60

   

 Semaglutide

R$ 774.00

R$ 1017.00

R$ 797.00

 

R$ 862.67

R$ 134.15

R$ 4.90

   

DPP4 inhibitors

       

R$ 21.13

2.304.84

911.00

 Vildagliptin 50 mg

R$ 80.89

R$ 68.98

R$ 63.90

 

R$ 71.26

R$ 8.72

R$ 8.55

   

 Sitagliptin 50 mg

R$ 116.03

R$ 142.23

  

R$ 129.13

R$ 18.53

R$ 10.33

   

 Alogliptin 25

R$ 75.88

R$ 67.42

R$ 63.03

 

R$ 68.77

R$ 6.53

    

 Linagliptin 5 mg

R$ 195.25

R$ 254.06

  

R$ 224.66

R$ 41.59

R$ 2.25

   

SGLT2 inhibitors

       

R$ 43.18

  

 Dapagliflozin 10 mg

R$ 99.80

R$ 95.60

R$ 147.99

 

R$ 114.46

R$ 29.11

R$ 17.86

 

1.373,52

542.89

 Empagliflozin 25 mg

R$ 182.89

R$ 251.59

R$ 282.08

R$ 182.89

R$ 224.86

R$ 50.03

R$ 25.32

   

Insulin

 Regular

R$ 21.00

R$ 23.12

R$ 23.76

 

R$ 22.63

R$ 1.45

R$ 1.13

R$ 1.13

  

 NPH

R$ 18.81

R$ 16.88

R$ 19.79

 

R$ 18.49

R$ 1.48

R$ 2.59

R$ 2.59

  

Total monthly cost in reais (Brazilian real – R$)

       

111.85

  

Total annual cost in reais (Brazilian real – R$)

       

1.342.21

  

Total annual cost in purchase parity-adjusted Int$

       

530.52

  
  1. Purchase power parity-adjusted conversion: 1 Int$ = 2, 53 R$. Final model considered only the prices for Dapagliflozin as this iSGLT2 was included in a government-led access program that significantly dropped its prices